(19)
(11) EP 4 771 051 A1

(12)

(43) Date of publication:
08.07.2026 Bulletin 2026/28

(21) Application number: 24777115.7

(22) Date of filing: 10.09.2024
(51) International Patent Classification (IPC): 
C07K 16/28(2006.01)
A61K 39/00(2006.01)
(52) Cooperative Patent Classification (CPC):
C07K 16/2875; A61K 2039/505; C07K 2317/92; C07K 2317/33; C07K 2317/565
(86) International application number:
PCT/US2024/045966
(87) International publication number:
WO 2025/059023 (20.03.2025 Gazette 2025/12)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
GE KH MA MD TN

(30) Priority: 12.09.2023 US 202363537933 P

(71) Applicant: AMGEN, INC.
Thousand Oaks, CA 91320-1799 (US)

(72) Inventors:
  • VANDER LUGT, Bryan
    Thousand Oaks, California 91320-1799 (US)
  • HASEGAWA, Haruki
    Thousand Oaks, California 91320-1799 (US)
  • ESTES, Bram
    Thousand Oaks, California 91320-1799 (US)
  • SORIANO, Brian D.
    Thousand Oaks, California 91320-1799 (US)
  • THOMSON, Christy Ann
    Thousand Oaks, 91320- 1799 (US)

(74) Representative: Schiweck Weinzierl Koch Patentanwälte Partnerschaft mbB 
Ganghoferstraße 68 B
80339 München
80339 München (DE)

   


(54) ANTI-CD30L ANTIBODIES AND USES THEREOF